12:00 AM
 | 
Nov 01, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Aptosyn exisulind: NDA under review

CLPA reported open-label 6-month extension data from 48 patients who participated in the company's Phase II/III study. In the 25 patients who received placebo during the trial and were switched to Aptosyn, there was a statistically significant...

Read the full 163 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >